Please note: The information displayed on this page might be outdated.
Amolyt Pharma: Amolyt Pharma (formerly Alizé Pharma 3) is building on its team’s established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Its portfolio includes AZP-3601 as a potential treatment of hypoparathyroidism and AZP-3404, which is undergoing indication prioritization work. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors.

In July 2019, a €67 million ($ 75M) Series A financing was led by LSP, and included Novo Ventures, Kurma Partners, Orbimed, Pontifax, Partners Innovation Fund, Innobio 2 and Turenne Capital / Sham Innovation Santé.
Based in...
Europe, US - New England
Disease Space
Rare Disease
15, chemin du Saquin, Espace Européen
Building G
Écully, 69 130

Company Participants at European Biotech Investor Day 2020

  • Patrick Loustau
  • Thierry Abribat, CEO & Founder